Home / Stocks / Shukra Pharmaceuticals L
SHUKRAPHAR

Shukra Pharmaceuticals L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹82.22

Change

+0.02 (0.02%)

Open

₹82.52

Prev. Close

₹82.2

Day High

₹83.0

Day Low

₹82.17

Volume Analysis

Traded

2,241,222

Delivered

1,430,954

Delivery %

63.85%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (28.9%)
  • •Strong operating margin (58.0%)

Weaknesses (0)

No signal for this stock

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹83.58 ₹83.29 ₹82.75 ₹82.46 ₹81.92 ₹81.63 ₹81.09
Fibonacci ₹83.29 ₹82.97 ₹82.78 ₹82.46 ₹82.14 ₹81.95 ₹81.63
Camarilla ₹82.45 ₹82.37 ₹82.3 ₹82.46 ₹82.14 ₹82.07 ₹81.99

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+0.02%

1 Month

+20.28%

3 Months

+86.61%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹5.5

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

19.02%

Net margin 38.94% × asset turnover 0.33x × equity multiplier 1.48x

Company Overview

Sector

Healthcare

Market Cap

₹3,639 Cr

P/E (TTM)

82.1

ROE

28.9%

Book Value

₹2.69

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Shukra Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (28.9%); strong operating margin (58.0%).

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Valuation

0

Cash Flow

3

Corporate Governance

60

Momentum

96

Institutional Ownership

30

Business Quality

100

Risk & Volatility

82

Liquidity

91

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 30.6 times its book value
  • −Debtor days have increased from 123 to 148 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Q2 FY27 revenue rose 652% to Rs44.20 crore; net profit increased to Rs16.01 crore.

Reg 32 04 Nov

No deviation in utilization of Rs 10.46 crore preferential warrant proceeds for Q2 FY27.

Board approved Q2/H1 FY27 results; name changed to Shukra Medtech, warrants converted.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 11 13 5 6 39 6 24 44
Expenses + 7 6 4 6 12 6 4 26
Operating Profit 4 7 1 0 27 1 19 19
OPM % 37.0% 55.0% 24.0% -7.0% 69.0% 11.0% 81.0% 42.0%
Other Income + 1 1 1 2 1 1 1 1
Interest 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1
Profit before tax 4 8 1 0 27 0 18 18
Tax % 23.0% 29.0% 26.0% -1,090.0% 24.0% 553.0% 29.0% 29.0%
Net Profit + 3 5 1 2 20 -2 13 13
EPS in Rs 0 0 0 0 0 0 0 0
Raw PDF — — — — — — — —
YoY Sales growth — — — — 270 -52 336 652

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2025 Mar 2026 TTM
Sales + 33 57 113
Expenses + 20 28 48
Operating Profit 13 29 66
OPM % 39.0% 51.0% 58.0%
Other Income + 4 5 3
Interest 1 1 1
Depreciation 3 3 4
Profit before tax 13 29 63
Tax % 28.0% 23.0% —
Net Profit + 10 22 44
EPS in Rs 0 1 1
Dividend Payout % 5.0% 2.0% —
Sales growth — 74 222

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2025 Mar 2026 Sep 2026
Reserves 19 46 74
Borrowings + 4 5 22
Other Liabilities + 20 23 34
Total Liabilities 87 117 175
Fixed Assets + 19 22 21
CWIP 2 12 26
Investments 0 0 0
Other Assets + 65 84 128
Total Assets 87 117 175
Equity Capital 44 44 44

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2025 Mar 2026
Cash from Operating Activity + 8 3
Cash from Investing Activity + -1 -14
Cash from Financing Activity + -5 5
Net Cash Flow 2 -6
Free Cash Flow 5 -13
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 92 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.95% → 51.16%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.92% 48.93% 48.2%
Promoters 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 51.16%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.43%
DII 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.21%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Shukra Pharmaceuticals L (this stock) 3,639 82.1 30.56 28.9%
Unichem Laboratories Ltd 3,511 29.5 1.26 3.17%
Solara Active Pha Sci Ltd 3,347 70.7 2.33 -0.13%
Advanced Enzyme Tech Ltd 3,102 19.1 1.9 10.5%
Rpg Life Sciences Ltd 4,310 37.6 6.26 19.3%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%
Ind Swift Laboratories Lt 2,881 31.4 1.95 4.02%

Which Mutual Funds Hold Shukra Pharmaceuticals L?

Frequently Asked Questions about Shukra Pharmaceuticals L

Community Sentiment

What are other investors saying about Shukra Pharmaceuticals L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.